Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease

Naturally occurring biological entities with extractable and tunable structural and functional characteristics, along with therapeutic attributes, are of supreme interest for strengthening the twenty-first-century biomedical settings. Irrespective of ongoing technological and clinical advancement, traditional medicinal practices to address and manage inflammatory bowel disease (IBD) are inefficient and the effect of the administered therapeutic cues is limited. The reasonable immune response or invasion should also be circumvented for successful clinical translation of engineered cues as highly efficient and robust bioactive entities. In this context, research is underway worldwide, and researchers have redirected or regained their interests in valorizing the naturally occurring biological entities/resources, for example, algal biome so-called "treasure of untouched or underexploited sources". Algal biome from the marine environment is an immense source of excellence that has also been demonstrated as a source of bioactive compounds with unique chemical, structural, and functional features. Moreover, the molecular modeling and synthesis of new drugs based on marine-derived therapeutic and biological cues can show greater efficacy and specificity for the therapeutics. Herein, an effort has been made to cover the existing literature gap on the exploitation of naturally occurring biological entities/resources to address and efficiently manage IBD. Following a brief background study, a focus was given to design characteristics, performance evaluation of engineered cues, and point-of-care IBD therapeutics of diverse bioactive compounds from the algal biome. Noteworthy potentialities of marine-derived biologically active compounds have also been spotlighted to underlying the impact role of bio-active elements with the related pathways. The current review is also focused on the applied standpoint and clinical translation of marine-derived bioactive compounds. Furthermore, a detailed overview of clinical applications and future perspectives are also given in this review.

Marine Seaweed Polysaccharides-Based Engineered Cues for the Modern Biomedical Sector

Seaweed-derived polysaccharides with unique structural and functional entities have gained special research attention in the current medical sector. Seaweed polysaccharides have been or being used to engineer novel cues with biomedical values to tackle in practice the limitations of counterparts which have become ineffective for 21st-century settings. The inherited features of seaweed polysaccharides, such as those of a biologically tunable, biocompatible, biodegradable, renewable, and non-toxic nature, urge researchers to use them to design therapeutically effective, efficient, controlled delivery, patient-compliant, and age-compliant drug delivery platforms. Based on their significant retention capabilities, tunable active units, swelling, and colloidal features, seaweed polysaccharides have appeared as highly useful materials for modulating drug-delivery and tissue-engineering systems. This paper presents a standard methodological approach to review the literature using inclusion-exclusion criteria, which is mostly ignored in the reported literature. Following that, numerous marine-based seaweed polysaccharides are discussed with suitable examples. For the applied perspectives, part of the review is focused on the biomedical values, i.e., targeted drug delivery, wound-curative potential, anticancer potentialities, tissue-engineering aspects, and ultraviolet (UV) protectant potential of seaweed polysaccharides based engineered cues. Finally, current challenges, gaps, and future perspectives have been included in this review.